Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Наслов
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Идентификатор
/unibl/sci/idNaucniRad:24618
Тип
Пронађите сличне уносеAcademic Article
Датум
Пронађите сличне уносе2016-09
Библиографски цитат
C. Hee Suh, A. Berrocal Kasay, E. Chalouhi El-Khouri, P. Miranda, LJ. Božić, S. Jeka, P. Hrycaj, D. Rekalov, P. Wiland, A. Krause, I. Szombati, A. Mihailova, I. Hospodarskyy, M. Piotrowski, S. Ryul Kwon, E. Young Lee, D. Hyun Yoo, W. Park, S. Cheol Shim, S. Joon Lee, T. S. Kwon, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, American college of rheumatology, pp. 100 - 101, Sep, 2016
Почетна страница
100
Крајња страница
101
Је дио
Пронађите сличне уносеAmerican college of rheumatology
Пронађите сличне уносеxxxx-xxxx
Листа аутора
Position: 11793 (34 views)